• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂1、玻连蛋白与凝血酶或组织型纤溶酶原激活物之间复合物的组成。

The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.

作者信息

van Meijer M, Stoop A, Smilde A, Preissner K T, van Zonneveld A J, Pannekoek H

机构信息

Department of Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands.

出版信息

Thromb Haemost. 1997 Mar;77(3):516-21.

PMID:9066004
Abstract

Vitronectin (VN) is an obligatory cofactor for the inhibition of thrombin by plasminogen activator inhibitor 1 (PAI-1). It accelerates the rate of association between thrombin and PAI-1 more than two orders of magnitude. In contrast, VN does not accelerate the association between tissue-type plasminogen activator (t-PA) and PAI-1. Previously, we reported that the anti-PAI-1 monoclonal antibody (MoAb) CLB-2C8 binds to a short stretch of amino acids of PAI-1, located between residues 128 and 145, and prevents PAI-1 binding to VN. Furthermore, MoAb CLB-2C8 fully blocks the inhibitory activity of PAI-1 towards t-PA, emphasizing the importance of this area for the interaction with t-PA. Here, we show that this area is also required for the interaction between thrombin and PAI-1, since MoAb CLB-2C8 fully prevents inhibition of thrombin by PAI-1. In spite of similar structural requirements for the interaction between t-PA, PAI-1 and VN and between thrombin, PAI-1 and VN, the intermediate reaction products are clearly distinct. By employing surface plasmon resonance (SPR), using the BIAcore equipment, and by immunoprecipitation we demonstrate that, in the presence of VN, t-PA and PAI-1 form exclusively equimolar binary t-PA/PAI-1 complexes. Thrombin, PAI-1 and VN generate equimolar, binary thrombin/PAI-1 complexes and in addition equimolar, ternary complexes and multimers.

摘要

纤连蛋白(VN)是纤溶酶原激活物抑制剂1(PAI - 1)抑制凝血酶的必需辅因子。它将凝血酶与PAI - 1之间的结合速率提高了两个多数量级。相比之下,VN不会加速组织型纤溶酶原激活物(t - PA)与PAI - 1之间的结合。此前,我们报道抗PAI - 1单克隆抗体(MoAb)CLB - 2C8与PAI - 1位于第128至145位残基之间的一小段氨基酸结合,并阻止PAI - 1与VN结合。此外,MoAb CLB - 2C8完全阻断了PAI - 1对t - PA的抑制活性,强调了该区域对于与t - PA相互作用的重要性。在此,我们表明该区域对于凝血酶与PAI - 1之间的相互作用也是必需的,因为MoAb CLB - 2C8完全阻止了PAI - 1对凝血酶的抑制。尽管t - PA、PAI - 1与VN之间以及凝血酶、PAI - 1与VN之间的相互作用有相似的结构要求,但中间反应产物明显不同。通过使用BIAcore设备进行表面等离子体共振(SPR)以及免疫沉淀,我们证明,在VN存在的情况下,t - PA和PAI - 1仅形成等摩尔的二元t - PA/PAI - 1复合物。凝血酶、PAI - 1和VN生成等摩尔的二元凝血酶/PAI - 1复合物,此外还生成等摩尔的三元复合物和多聚体。

相似文献

1
The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.纤溶酶原激活物抑制剂1、玻连蛋白与凝血酶或组织型纤溶酶原激活物之间复合物的组成。
Thromb Haemost. 1997 Mar;77(3):516-21.
2
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.组织型纤溶酶原激活物的可变区-1通过促进催化作用赋予纤溶酶原激活物抑制剂-1对凝血酶的特异性:由异源蛋白质表面环解除动力学阻滞。
J Mol Biol. 1999 Oct 29;293(3):613-27. doi: 10.1006/jmbi.1999.3178.
3
Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.纤溶酶原激活物抑制剂1含有一个隐蔽的高亲和力受体结合位点,该位点在与组织型纤溶酶原激活物形成复合物时暴露出来。
Thromb Haemost. 1998 Nov;80(5):822-8.
4
Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.与普通肝素相比,低分子量肝素对凝血酶依赖性纤溶酶原激活物抑制剂1失活的增强作用较弱。
Thromb Haemost. 2006 Apr;95(4):637-42.
5
Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.噬菌体展示的高突变纤溶酶原激活物抑制剂1(PAI-1)文库证明,潜伏期转变和蛋白酶抑制过程中PAI-1的不同结构要求。
J Mol Biol. 2001 Jan 26;305(4):773-83. doi: 10.1006/jmbi.2000.4356.
6
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.纤溶酶原激活物抑制剂-1(PAI-1)与玻连蛋白(Vn)的相互作用:确定PAI-1和Vn上的结合位点
Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. doi: 10.1515/BC.2002.125.
7
Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.通过定点诱变鉴定1型纤溶酶原激活物抑制剂低分子量抑制剂的结合位点。
Biochemistry. 1998 Feb 3;37(5):1227-34. doi: 10.1021/bi971554q.
8
Localization of a vitronectin binding region of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1玻连蛋白结合区域的定位
Thromb Haemost. 1995 May;73(5):829-34.
9
Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?游离及与抑制剂结合的组织型纤溶酶原激活剂的细胞降解——是否需要共同受体?
Thromb Haemost. 2000 Feb;83(2):290-6.
10
Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.伤口诱导的MDA-MB-435和SKOV-3癌细胞迁移受纤溶酶原激活物抑制剂-1调控。
Int J Oncol. 2005 Sep;27(3):749-57.

引用本文的文献

1
Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.纤溶酶原激活物抑制剂 1 在“分子三明治”复合物中得到显著稳定。
Biochemistry. 2013 Jul 9;52(27):4697-709. doi: 10.1021/bi400470s. Epub 2013 Jun 25.